GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (STU:6Y4) » Definitions » Operating Margin %

Vicore Pharma Holding AB (STU:6Y4) Operating Margin % : -1,842.34% (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Vicore Pharma Holding AB Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Vicore Pharma Holding AB's Operating Income for the three months ended in Dec. 2024 was €-8.18 Mil. Vicore Pharma Holding AB's Revenue for the three months ended in Dec. 2024 was €0.44 Mil. Therefore, Vicore Pharma Holding AB's Operating Margin % for the quarter that ended in Dec. 2024 was -1,842.34%.

The historical rank and industry rank for Vicore Pharma Holding AB's Operating Margin % or its related term are showing as below:

STU:6Y4' s Operating Margin % Range Over the Past 10 Years
Min: -8186.22   Med: -780.4   Max: -174.09
Current: -177.59


STU:6Y4's Operating Margin % is ranked worse than
54.85% of 990 companies
in the Biotechnology industry
Industry Median: -124.93 vs STU:6Y4: -177.59

Vicore Pharma Holding AB's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Vicore Pharma Holding AB's Operating Income for the three months ended in Dec. 2024 was €-8.18 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2024 was €-17.02 Mil.


Vicore Pharma Holding AB Operating Margin % Historical Data

The historical data trend for Vicore Pharma Holding AB's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB Operating Margin % Chart

Vicore Pharma Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -174.09

Vicore Pharma Holding AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 22.22 - - -1,842.34

Competitive Comparison of Vicore Pharma Holding AB's Operating Margin %

For the Biotechnology subindustry, Vicore Pharma Holding AB's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicore Pharma Holding AB's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's Operating Margin % falls into.


;
;

Vicore Pharma Holding AB Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Vicore Pharma Holding AB's Operating Margin % for the fiscal year that ended in Dec. 2024 is calculated as

Operating Margin %=Operating Income (A: Dec. 2024 ) / Revenue (A: Dec. 2024 )
=-16.549 / 9.506
=-174.09 %

Vicore Pharma Holding AB's Operating Margin % for the quarter that ended in Dec. 2024 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=-8.18 / 0.444
=-1,842.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vicore Pharma Holding AB  (STU:6Y4) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Vicore Pharma Holding AB Operating Margin % Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vicore Pharma Holding AB Business Description

Traded in Other Exchanges
Address
Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines